recombinant human factor VII (Weiguang Biological Products)

Recombinant human factor VII is a recombinant protein replacement therapy being developed by **Weiguang Biological Products** for the treatment of bleeding disorders, specifically **congenital factor VII deficiency**. The drug is produced using a **piggyBac transposon** expression system in **Chinese Hamster Ovary (CHO) cells**, a method highlighted in the company's research and development portfolio. As a replacement therapy, it functions by restoring the extrinsic pathway of the coagulation cascade. Once administered intravenously, the activated form of Factor VII (FVIIa) complexes with tissue factor (TF) to activate Factor X and Factor IX, ultimately leading to thrombin generation and the formation of a stable fibrin clot to achieve hemostasis.

Other names

recombinant FVIIrFVIIrecombinant human coagulation factor VII